IMU-838 not checked

Immunic AG · IM90838

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
3 active
7 in total · 5 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“* Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 15 mg tablet IMU-838 daily) and then start taking the full assigned dose from Day 7 onwards (two 15 mg tablets IMU-838 once daily). * Optional extended treatment period (optional): Participants who were re-randomized to a 30 mg/day dose will take the full assigned…”In the company’s words, NCT03846219 on ClinicalTrials.gov
Tested for
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Relapsing-Remitting Multiple Sclerosis (RRMS)
Main trialPhase 3
“Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)”In the company’s words, NCT05134441 on ClinicalTrials.gov
Other names
IM90838 · vidofludimus calcium

Other drugs for Multiple Sclerosis

All 54 drugs for Multiple Sclerosis

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials7

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Nov 2026 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Phase 3Active, not recruiting Nov 2026 Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Phase 2Active, not recruiting 24 Apr 2020 MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)
Phase 2/3Completed 12 Jan 2021 A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)
Phase 2Terminated 16 Nov 2022 Phase 2 Dose-finding IMU-838 for Ulcerative Colitis
Phase 2Unknown 7 Jan 2025 Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
Phase 2Ended not given Randomized adaptive assessment of post COVID syndrome treatments (RAPID) Reducing Inflammatory Activity in Patients with post COVID Syndrome (REVIVE)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow IMU-838

Following is part of Solo: you see every change to IMU-838 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in